Seroatlas · Human Serome Atlas

VIL1

Villin-1

Also known as: D2S1471, VIL, VILI_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P09327
Gene
VIL1
Ensembl
ENSG00000127831
Chromosome
2
Canonical length
827 aa
Protein class
Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Plasma membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene encodes a member of a family of calcium-regulated actin-binding proteins. This protein represents a dominant part of the brush border cytoskeleton which functions in the capping, severing, and bundling of actin filaments. Two mRNAs of 2.7 kb and 3.5 kb have been observed; they result from utilization of alternate poly-adenylation signals present in the terminal exon. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

827 residues, UniProt reviewed canonical sequence.

>P09327|VIL1
     1  MTKLSAQVKG SLNITTPGLQ IWRIEAMQMV PVPSSTFGSF FDGDCYIILA IHKTASSLSY
    61  DIHYWIGQDS SLDEQGAAAI YTTQMDDFLK GRAVQHREVQ GNESEAFRGY FKQGLVIRKG
   121  GVASGMKHVE TNSYDVQRLL HVKGKRNVVA GEVEMSWKSF NRGDVFLLDL GKLIIQWNGP
   181  ESTRMERLRG MTLAKEIRDQ ERGGRTYVGV VDGENELASP KLMEVMNHVL GKRRELKAAV
   241  PDTVVEPALK AALKLYHVSD SEGNLVVREV ATRPLTQDLL SHEDCYILDQ GGLKIYVWKG
   301  KKANEQEKKG AMSHALNFIK AKQYPPSTQV EVQNDGAESA VFQQLFQKWT ASNRTSGLGK
   361  THTVGSVAKV EQVKFDATSM HVKPQVAAQQ KMVDDGSGEV QVWRIENLEL VPVDSKWLGH
   421  FYGGDCYLLL YTYLIGEKQH YLLYVWQGSQ ASQDEITASA YQAVILDQKY NGEPVQIRVP
   481  MGKEPPHLMS IFKGRMVVYQ GGTSRTNNLE TGPSTRLFQV QGTGANNTKA FEVPARANFL
   541  NSNDVFVLKT QSCCYLWCGK GCSGDEREMA KMVADTISRT EKQVVVEGQE PANFWMALGG
   601  KAPYANTKRL QEENLVITPR LFECSNKTGR FLATEIPDFN QDDLEEDDVF LLDVWDQVFF
   661  WIGKHANEEE KKAAATTAQE YLKTHPSGRD PETPIIVVKQ GHEPPTFTGW FLAWDPFKWS
   721  NTKSYEDLKA ELGNSRDWSQ ITAEVTSPKV DVFNANSNLS SGPLPIFPLE QLVNKPVEEL
   781  PEGVDPSRKE EHLSIEDFTQ AFGMTPAAFS ALPRWKQQNL KKEKGLF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VIL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.28
Highest tissue expression
411 nTPM

Expression across tissuesHPA

Tissue

  • small intestine: 411 nTPM
  • duodenum: 371 nTPM
  • rectum: 172 nTPM
  • colon: 165 nTPM
  • liver: 29 nTPM
  • pancreas: 28 nTPM

Single-cell type

  • enterocytes: 559 nCPM
  • colonocytes: 252 nCPM
  • enteric transient amplifying cells: 180 nCPM
  • enteric stem cells: 167 nCPM
  • goblet cells: 160 nCPM
  • tuft cells: 150 nCPM

Immune cell

  • total PBMC: 4 nTPM
  • neutrophil: 1.3 nTPM
  • basophil: 0.3 nTPM
  • plasmacytoid DC: 0.2 nTPM
  • myeloid DC: 0.1 nTPM
  • classical monocyte: 0 nTPM

Brain region

  • cerebellum: 1.3 nTPM
  • cerebral cortex: 1.1 nTPM
  • basal ganglia: 0.8 nTPM
  • hippocampal formation: 0.8 nTPM
  • white matter: 0.8 nTPM
  • amygdala: 0.7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about VIL1.

Disease | ImmuneIEDB

Conditions an epitope on VIL1 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.86
gnomAD pLI
0
gnomAD missense Z
0.9
DepMap mean gene effect
-0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VIL1 as an antibody target. Whether an autoantibody or antibody against VIL1 could matter depends on whether native VIL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VIL1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label VIL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/VIL1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...